还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

3 J  m0 ^7 S4 n6 A4 {, g4 z请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

; s4 j$ }9 T; J! ^. K- o6 Z可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  

+ c- l  V9 _# K: \% F
1 U1 k9 S0 z. t1 U! Q- NSub-category:
Molecular Targets
  d/ h5 g- j9 m+ ^- z9 s' `  O
7 F6 z6 N: Y5 `* P3 S
% {" V: K) D" V1 qCategory:
Tumor Biology
0 B+ n( t7 r$ I. K) K

Meeting:
3 x6 @$ z, n+ M4 |2 o% R) @6 F3 i2011 ASCO Annual Meeting


5 P: X1 p& x" L, x2 {9 A. ]2 S. X0 zSession Type and Session Title:
Poster Discussion Session, Tumor Biology
+ U3 T; P! i5 v* f- T

7 |9 I6 v: q) m5 e7 yAbstract No:
10517

: M6 }2 O3 i  y! M& J  x
Citation:
+ D' d) q! w: O( hJ Clin Oncol 29: 2011 (suppl; abstr 10517)
5 c: s: l, F" n6 t
: }# F% y& C- c% n! I* P. @! w5 s
Author(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
7 J" Q: s; C: H

. P8 L) _& u- a
2 m' z) n& s- o  ^$ n3 T/ Q1 YAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

& K: i6 m! \! s* l; ]* fAbstract Disclosures

Abstract:
4 g6 |+ g/ S7 G0 S: E; S
- C6 R- U( z- b* U
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 q; Y5 ]9 ~! |3 _* K

  H6 S/ U  l7 D8 O

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

0 u% K! \( R- A9 t: w没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

! h0 G( l! R3 y0 J4 w+ \6 D平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

, [3 m% x5 |3 `' L9 T现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊